无细胞蛋白质合成作为一种快速选机器学习产生的蛋白酶变体的方法
Ella Lucille Thornton1, Jeremy T Boyle1, Nadanai Laohakunakorn1
1Centre for Engineering Biology, Institute of Quantitative Biology, Biochemistry and Biotechnology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, Scotland.
ACS synthetic biology
|April 30, 2025
概括
无细胞蛋白质合成提供了一种快速选蛋白质变体的方法,用于训练机器学习模型. 这种方法通过选随机和向变体,成功地改善了蛋白酶的动力特性.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 蛋白质工程是指蛋白质工程.
背景情况:
- 机器学习 (ML) 模型需要广泛的,高质量的数据来预测蛋白质结构,工程和设计.
- 传统的蛋白质净化用于数据生成是耗时和资源密集的,阻碍了ML可扩展性.
- 开发用于生成功能蛋白数据的高效方法对于在蛋白质科学中推进ML至关重要.
研究的目的:
- 将无细胞蛋白合成 (CFPS) 作为一种快速有效的工具,用于在ML工作流程中选蛋白质变体.
- 通过改善蛋白酶的动力性质来证明CFPS在优化蛋白质功能的应用.
- 验证CFPS作为探索蛋白质健身景观的可行方法.
主要方法:
- 利用无细胞蛋白质合成,快速生成和评估各种蛋白质变体的活性.
- 采用了初始随机变异选的策略,随后是有针对性的变异选择,以有效地探索蛋白质适应性格局.
- 蛋白酶变异的量化动力性质,以确定改进.
主要成果:
- 使用CFPS成功选了48种随机蛋白质变异和32种向变异.
- 确定了几种蛋白酶变体,表现出增强的动力性质.
- 证明了CFPS在识别有益蛋白质修饰的速度和有效性.
结论:
- 无细胞蛋白质合成是一种强大而高效的平台,用于生成查数据,以训练和完善蛋白质工程中的ML模型.
- CFPS加速发现具有改善功能特征的蛋白质变体,例如增强的酶动力学.
- 这种方法简化了ML驱动的蛋白质设计周期,减少了时间和资源需求.
更多相关视频
07:53A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
33.1K
07:35Rapid, Enzymatic Methods for Amplification of Minimal, Linear Templates for Protein Prototyping using Cell-Free Systems
Published on: June 14, 2021
2.6K
相关概念视频
01:57Protein Complexes with Interchangeable Parts
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
01:33Enzyme-Linked Immunosorbent Assay
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.